ITGB1 and prostate cancer: To assess the possible effects of MSCs on prostate cancer cells, we isolated mouse bone MSCs (CD29+SCA1+CD45Neg) and confirmed their stemness properties by performing osteoblastic, adipogenic, and chondrogenic differentiation assays (Supplementary Fig. 2).